Teva announced that Bendeka (bendamustine HCl) Injection is now available to replace Treanda (bendamustine HCl) Injection. 

Teva will continue to process orders for Treanda Injection through March 30, 2016, after which any submitted or open orders will be canceled. Treanda can still be dispensed until its expiration date. Treanda Injection 45mg/0.5mL and 180mg/2mL single-dose vials will be discontinued effective March 31, 2016. 

RELATED: Low-Volume Bendamustine Approved for CLL, NHL

Bendeka Injection is available as a 100mg/4mL strength solution multi-dose vials. Bendeka is a low-volume and short-time infusion (10 minutes) formulation of bendamustine, which is a bifunctional mechlorethamine derivative. It was approved by the Food and Drug Administration in December 2015 for the treatment of patients with chronic lymphocytic leukemia (CLL) and for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL). 

Treanda for Injection, which is the lyophilized formulation, will continue to be available for shipments. It is available as 25mg and 100mg strength single-dose vials.

For more information call (800) 896-5855 or visit